Research Article
MedChemComm
so as to optimize the treatment before docking and remove
the water molecules in the protein. A virtual cavity was built,
all small molecular ligands were prepared, and MOE's Dock
module to induced docking was used.
12 A. Arevalo-Martin and J. M. Vela, et al., Therapeutic action of
cannabinoids in a murine model of multiple sclerosis,
J. Neurosci., 2003, 23, 2511–2516.
13 D. Baker and G. Pryce, et al., Cannabinoids control spasticity
and tremor in a multiple sclerosis model, Nature, 2000, 404,
84–87.
Conflicts of interest
14 D. Kenneth and A. M. Bromberg, Design Logic of
a
There are no conflicts to declare.
Cannabinoid Receptor Signaling Network That Triggers
Neurite Outgrowth, Science, 2008, 320, 903–909.
15 C. Gratzke and T. Streng, et al., Cannabinor, a Selective
Cannabinoid-2 Receptor Agonist, Improves Bladder
Emptying in Rats with Partial Urethral Obstruction, J. Urol.,
2011, 185, 731–736.
16 M. G. Belvisi and H. J. Patel, et al., Inhibitory Activity of the
Novel CB2 Receptor Agonist, GW833972A, on Guinea-Pig
and Human Sensory Nerve Function in the Airways, Br. J.
Pharmacol., 2008, 155, 547–557.
17 S. Pasquini and C. Mugnaini, et al., Design, Synthesis, and
Pharmacological Characterization of Indol-3-ylacetamides,
Indol-3-yloxoacetamides, and Indol-3-ylcarboxamides: Potent
and Selective CB2 Cannabinoid Receptor Inverse Agonists,
J. Med. Chem., 2012, 55, 5391–5402.
Acknowledgements
The project was supported by The Natural Science Foundation
of the Jiangsu Higher Education Institutions of China (No.
17KJB350002, 17KJD520002), Science Foundation of Huaihai
Institute of Technology (No. Z2015012, Z2015015), Jiangsu
Key Laboratory of Marine Pharmaceutical Compound
Screening (No. HY2015B03, HY201703) Haiyan Plan of
Jiangsu Province Lianyungang City in 2017 and the Fifth
progress of “521” Project Funding of Lianyungang City in
2017.
Notes and references
1 R. G. Pertwee, Medical uses of cannabinoids: The way
forward, Addiction, 1999, 94, 317–320.
2 L. A. Matsuda, S. J. Lolait, M. J. Brownstein, A. C. Young and
T. I. Bonner, Structure of a cannabinoid receptor and
functional expression of the cloned cDNA, Nature, 1990, 346,
561–564.
3 S. Munro, K. L. Thomas and M. Abu-Shaar, Molecular
characterization of a peripheral receptor for cannabinoids,
Nature, 1993, 365, 61–65.
18 M. Soethoudt, U. Grether and J. Fingerle, et al., Cannabinoid
CB 2 receptor ligand profiling reveals biased signalling and
off-target activity, Nat. Commun., 2017, 8, 13958.
19 P. Morales, L. Hernandez-Folgado and P. Goya, et al.,
Cannabinoid receptor 2 (CB2) agonists and antagonists: a
patent update, Expert Opin. Ther. Pat., 2016, 26, 843–856.
20 N. Chadha and O. Silakari, Indoles as therapeutics of
interest in medicinal chemistry: Bird's eye view, Eur. J. Med.
Chem., 2017, 134, 159–184.
4 E. Ryberg, N. Larsson and S. Sjögren, et al., The orphan
receptor GPR55 is a novel cannabinoid receptor, Br. J.
Pharmacol., 2007, 152, 1092–1101.
5 A. G. Hohmann, R. L. Suplita and N. M. Bolton, et al., An
endocannabinoid mechanism for stress-induced analgesia,
Nature, 2005, 435, 1108.
6 Z. Shao and J. Yin, et al., High-resolution crystal structure of
the human CB1 cannabinoid receptor, Nature, 2016, 540,
602–606.
7 X. Li, T. Hua and K. Vemuri, et al., Crystal Structure of the
Human Cannabinoid Receptor CB2, Cell, 2019, 176, 1–9.
8 A. C. Howlett, The cannabinoid receptors, Prostaglandins
Other Lipid Mediators, 2002, 68, 619–631.
9 M. Rajesh and P. Mukhopadhyay, et al., CB2 cannabinoid
receptor agonists attenuate TNF-alpha-induced human
vascular smooth muscle cell pro1iferation and migration, Br.
J. Pharmacol., 2008, 153, 347–357.
10 R. P. Picone and D. A. Kendall, Minireview: From the Bench,
toward the Clinic: Therapeutic Opportunities for
Cannabinoid Receptor Modulation, Mol. Endocrinol.,
2015, 29, 801–813.
11 A. Scutt and E. M. Williamson, Cannabinoids stimulate
fibroblastic colony formation by bones marrow cells
indirectly via CB2 receptors, Calcif. Tissue Int., 2007, 80,
50–59.
21 D. Pagé, H. Yang, W. Brown, C. Walpole, M. Fleurent and M.
Fyfe, et al., New 1,2,3,4-tetrahydropyrroloij3, 4-b]indole
derivatives as selective CB2 receptor agonists, Bioorg. Med.
Chem. Lett., 2007, 17, 6183–6187.
22 P. Diaz, J. Xu, F. Astruc-Diaz, H.-M. Pan, D. L. Brown and M.
Naguib, Design and Synthesis of a Novel Series of N-Alkyl
Isatin Acylhydrazone Derivatives that Act as Selective
Cannabinoid Receptor 2 Agonists for the Treatment of
Neuropathic Pain, J. Med. Chem., 2008, 51, 4932–4947.
23 T. E. D'Ambra, K. G. Estep, M. R. Bell, M. A. Eissenstat and
K. A. Josef, et al., Conformationally Restrained Analogs of
Pravadoline:
Nanomolar
Potent,
Enantioselective,
(Aminoalkyl)indole Agonists of the Cannabinoid Receptor,
J. Med. Chem., 1992, 35, 124–135.
24 R. A. Ross, H. C. Brockie, L. A. Stevenson, V. L. Murphy, F.
Templeton, A. Makriyannis and R. G. Pertwee, Agonist-
inverse agonist characterization at CB1 and CB2
cannabinoid receptors of L759633, L759656, and AM630, Br.
J. Pharmacol., 1999, 126, 665–672.
25 M. Gallant, Y. Gareau, D. Guay, M. Labelle and P. Prasit,
Indole derivatives with affinity for the cannabinoid receptor,
US5532237, 1996.
26 J. M. Frost, M. J. Dart, K. R. Tietje, T. R. Garrison, G. K.
Grayson
and
A.
V.
Daza,
et
al.,
Indol-3-yl-
tetramethylcyclopropyl Ketones: Effects of Indole Ring
1946 | Med. Chem. Commun., 2019, 10, 1935–1947
This journal is © The Royal Society of Chemistry 2019